表3. Lp-PLA2在预测心血管疾病的优势
六、化学发光法检测优势
新产业生物是目前化学发光厂家中，可检测项目最多的厂家。深圳市南山医院就深圳新产业生物Lp-PLA2检测试剂（发光法）与目前临床上最常用的DiaDexus公司的PLAC ELISA法进行了性能指标的比对，并将比对结果发表于权威杂志CCA。对122个临床样本的检测，新产业化学发光法与DiaDexus公司检测结果具有显著的相关性（R2=0.979）[12]；与PLAC ELISA法相比，新产业化学发光法检测速度更快，17分钟即可出首个结果；检测范围更广，检测灵敏度更高，优于酶免等其他方法学，完全满足临床需求。
图6.新产业生物与DiaDexus ELISA相关性分析[12]
“小钢炮”MAGLUMI® X3
为急诊项目应运而生
MAGLUMI® X3是新产业生物公司在2020年成功推出的一款全自动化学发光分析仪，该仪器秉承X系列外观设计理念，简约、实用、富有科技感。作为MAGLUMI® X8的兄弟产品，其优异的性能与X8一脉相承。X系列已获得115件专利，采用当今尖端科技，并融入新一代ABS（All Balanced and Strong）理念，全局考虑，巧妙设计，各项性能都处于领先水平，非常适合急诊项目的检测。其主要特点如下：
精确定量：MAGLUMI® X3 应用国际先进的直接化学发光检测技术，精确定量检测，结果准确，重复性好；与检验科、中心实验室的国际主流大型化学发光分析仪结果一致；
占地面积小：MAGLUMI® X3占地面积小，不到0.68m2，解决了门/急诊组、急诊室空间有限的问题；
检测速度快：MAGLUMI® X3检测速度200T/H，台式机中检测速度领先；
支持多种标本类型：血清、血浆；
可以检测包括心肌标志物、甲状腺功能、性激素、肿瘤标志物、传染病、自免抗体、炎症、肾功能、糖代谢等141个项目（已注册）。
新产业生物提供心血管及心肌标志物检测完美的解决方案
适用于急诊科全自动化学发光分析系统，病人标本做完血常规离心后，可同时精确、定量、快速检测心血管及心肌标志物。
【参考文献】
[1] 中国老年学学会心脑血管病专业委员会,中国检验学会检验医师分会心脑血管病专业委员会.脂蛋白相关磷脂酶A2临床应用中国专家建议[J].中华心血管病杂志.2015,10.43(10): 843-847.
[2] Ross R, John A, et al.The Pathogenesis of Atherosclerosis-(First of Two Parts)[J]. N Engl J Med, 1976, 295(7): 369-77.
[3] GreenlandP, AlpertJS,BellerGA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2010, 56(25): e50–e103.
[4] GoldsteinLB, BushnellCD, AdamsRJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2011, 42(2): 517–584.
[5] Marshall A, Corson, MD,et al. Review of the Evidence for the Clinical Utility of LipoproteinAssociated Phospholipase A2 as a Cardiovascular Risk Marker[J]. Am J Card Suppl 2008:101 (41F-50F)
[6] Marc S, David A, et al. Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease[J].Journal of The American Heart Association, 2007, 27:2463-2469.
[7] Lipoprotein-associated phospholipase A2 and risk of coronary disease,stroke,and mortality: collaborative analysis of 32 prospective studies[J]. Lancet,2010, 375(9725):1536-1544.
[8] Michelle A, Robert J, et al. The effect of statin therapy on lipoprotein associated phospholipase A2 levels[J]. Atherosclerosis, 2005, 182(1): 193-198.
[9] Sullivan L M, Massaro J M, D’Agostino R B. Presentation of multivariate data for clinical use: The Framingham Study risk score functions[J]. 2004.
[10] Muriel, J, Caslake, et al. Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)[J]. Atherosclerosis, 2010, 210(1):28-34.
[11] Gregson J, Stirnadel-Farrant H A, Doobaree I U, et al. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors:A systematic review of the literature[J]. Atherosclerosis, 2012, 225(1).
[12] Chen J, Zhang H, Chen W. Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation[J]. Clin Chim Acta, 2019,488:143-149.
